[{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"6e3accdd-5a43-478f-a02d-784bf9cd8ce5","acronym":"NCI-2018-00876","url":"https://clinicaltrials.gov/study/NCT03528642","created_at":"2021-01-18T17:22:22.349Z","updated_at":"2024-07-02T16:34:37.431Z","phase":"Phase 1","brief_title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","source_id_and_acronym":"NCT03528642 - NCI-2018-00876","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"9846d54e-e208-4079-8aa7-1c8885707b2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03831932","created_at":"2023-11-19T11:15:17.732Z","updated_at":"2024-07-02T16:35:02.404Z","phase":"Phase 1/2","brief_title":"Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03831932","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-21"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"290f9c1c-d70d-4aad-827e-5424eb25383a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047993","created_at":"2021-01-17T17:15:53.781Z","updated_at":"2024-07-02T16:35:03.817Z","phase":"Phase 1/2","brief_title":"Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome","source_id_and_acronym":"NCT03047993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH1 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH1 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 03/16/2023","primary_completion_date":" 03/16/2023","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2024-05-14"},{"id":"a6296e1c-a354-4e7b-92ff-b1610788e48a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02861300","created_at":"2021-01-18T14:02:43.613Z","updated_at":"2024-07-02T16:35:43.089Z","phase":"Phase 1/2","brief_title":"CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer","source_id_and_acronym":"NCT02861300","lead_sponsor":"David Bajor","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 09/12/2016","start_date":" 09/12/2016","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-07-13"},{"id":"ba6bfc19-17c6-4180-ab58-5f25cec2217a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03263429","created_at":"2021-01-18T16:07:15.229Z","updated_at":"2024-07-02T16:35:54.025Z","phase":"Phase 1/2","brief_title":"Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer","source_id_and_acronym":"NCT03263429","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • irinotecan • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-06"},{"id":"e89fe2f4-7314-46f1-905d-b68e2ca76785","acronym":"","url":"https://clinicaltrials.gov/study/NCT03057600","created_at":"2021-01-18T15:03:33.793Z","updated_at":"2024-07-02T16:36:03.292Z","phase":"Phase 2","brief_title":"Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT03057600","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • albumin-bound paclitaxel • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2022-09-28"},{"id":"c4d79bb8-8b6f-470a-8b96-2d4499daedea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965845","created_at":"2021-01-18T19:30:39.173Z","updated_at":"2024-07-02T16:36:03.785Z","phase":"Phase 1b/2","brief_title":"A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors","source_id_and_acronym":"NCT03965845","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" KRAS • CDKN2A","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • CDKN2A mutation","tags":["KRAS • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 06/25/2019","start_date":" 06/25/2019","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2022-09-19"},{"id":"c3a24330-ab2b-4331-846e-04b0a70a485b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04824937","created_at":"2021-04-01T16:52:19.042Z","updated_at":"2024-07-02T16:36:32.558Z","phase":"Phase 2","brief_title":"Telaglenastat + Talazoparib In Prostate Cancer","source_id_and_acronym":"NCT04824937","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • telaglenastat (CB-839)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2021-04-01"}]